Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001213900-25-020316·BridgeBio Oncology Therapeutics, Inc.
Schedule 13D ownership disclosure
HELIX ACQUISITION CORP II
Class A ordinary shares, $0.0001 par value per share · CUSIP: G4444H101
Event date: 2025-02-28
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Helix Holdings II LLCReported CIK 0001869101
Shares: 4,989,000.00 · Class: 21.33%
- Cormorant Private Healthcare Fund III, LPReported CIK 0001817320
Shares: 1,427,040.00 · Class: 7.55%
- Cormorant Private Healthcare GP III, LLC
Shares: 1,427,040.00 · Class: 7.55%
- Bihua ChenReported CIK 0001599214
Shares: 7,389,000.00 · Class: 31.59%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-020316
- Form type
- SCHEDULE 13D/A
- Filer
- BridgeBio Oncology Therapeutics, Inc.
- CIK
- CIK 1869105
- Filed
- Mar 04, 2025
- Reporting period
- Feb 28, 2025
- Description
- Schedule 13D beneficial ownership